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I
 
n this issue of 
 
The Journal of Experimental Medicine
 
 (1), Al-
fano et al. report the surprising results that pertussis toxin
(PTX) as well as its cellular binding subunit, the B-oligo-
mer, each blocked entry of monotropic (R5) strains of
HIV-1 in primary T lymphocytes. Treatment of primary T
cells with B-oligomer, unlike treatment of T cell lines,
blocked calcium mobilization in response to the CCR5
 
chemokine ligand macrophage inflammatory protein-1
 
b
 
(MIP-1
 
b
 
), but had no effect on cell surface expression of
CCR5 and binding of MIP-1
 
b
 
 or HIV-1 envelope gp120.
Alfano et al. further demonstrate that B-oligomer blocks
cocapping of CCR5 and CD4 induced by R5 HIV-1, but
does not affect cocapping of CXCR4 and CD4 after incu-
bation with T tropic (X4) virus. They documented that the
B-oligomer signals by itself and induces calcium mobiliza-
tion in primary T lymphocytes. Based on these activating
effects, the authors hypothesize that the inhibitory effect of
B-oligomer is probably a consequence of cross-desensitiza-
tion of CCR5, although the cellular receptor for B-oligo-
mer has not yet been defined. These findings argue for the
requirement of an intact signaling capacity for CCR5 to act
as an HIV-1 fusion coreceptor in primary T cells and sug-
gest a novel approach to the design of therapeutic inhibi-
tors of CCR5. There are a number of research reports that
provide added insights concerning the mechanistic basis for
these provocative findings.
The current model of the HIV-1 fusion predicts that af-
ter binding of the envelope gp120 to the CD4 molecule, a
conformational change in gp120 ensues, which enables its
critical domain (or domains) to engage one of the chemo-
kine receptors. This process is necessary for the fusogenic
conversion of HIV-1 gp41 and the exposure of its fusion
peptide domain (2, 3). The usage of chemokine receptors
by HIV-1 Env and the ability of receptor-specific chemo-
kine ligands to prevent HIV-1 fusion and infection raised
the question whether the process of HIV-1 fusion is passive
or requires chemokine receptor signals. A number of stud-
ies of CCR5 have suggested that chemokine receptor sig-
naling may be dispensable for its role as an HIV-1 fusion
coreceptor (4–6). For example, PTX did not interfere with
the capacity of HIV-1 to infect T cell lines in vitro. Fur-
thermore, truncation of the COOH tail of CCR5 or muta-
tion of the highly conserved aspartate-arginine-tyrosine
(DRY) sequence in the second cytoplasmic loop each ef-
fectively blocked chemokine-dependent activation of clas-
sical second messengers, intracellular calcium mobilization,
and cell migration in response to CCR5 chemokine
ligands. Yet none of these mutations altered the ability of
CCR5 to support HIV-1 entry (7). Similar truncations or
mutations of CXCR4 also did not alter its function as a
coreceptor for the X4 HIV-1 (8). These results lead to the
conclusion that G protein–coupled signaling, a conse-
quence of CCR5 and CXCR4 activation by their che-
mokine ligands, was not involved in the process of HIV-1
fusion. Thus, CCR5 or CXCR4 was considered to merely
play a passive role as an anchor for HIV-1 envelope protein
based on their association with the CD4 molecules on the
cell membrane (9, 10).
Although HIV-1 apparently does not require an intact
chemokine coreceptor signaling capacity for cell entry, sev-
eral lines of evidence have shown that HIV-1 envelope
(Env) proteins nevertheless activate G proteins through
their interaction with CCR5 or CXCR4. The chemotac-
tic and calcium mobilizing activity of soluble gp120 for
 
CD4
 
1
 
 T lymphocytes and monocytes were documented
more than a decade ago (11). Recently, Weissman et al. re-
ported that mammalian cell–derived recombinant R5
 
HIV-1 Env was able to induce Ca
 
2
 
1
 
 flux and migration in
cultured primary CD4
 
1
 
 T cells (12). Since the signaling of
HIV-1 Env in CD4
 
1
 
 T cells could be specifically desensi-
tized by the CCR5 ligand MIP-1
 
b
 
, it was concluded that
this R5 HIV-1 Env activated CCR5 in the presence of
CD4 (12). Unlike R5 HIV-1 Env, the X4 HIV-1 gp120
seems to be able to activate CXCR4 in the absence of
CD4 by inducing migration and Ca
 
2
 
1
 
 flux in both CD4
 
1
 
and CD8
 
1
 
 T lymphocytes (13, 14).
There is considerable evidence that HIV-1 and envelope
proteins have the capacity to induce signal transduction
events independent of G
 
i
 
 proteins. HIV-1 gp120 of both
R5 and X4 strains has been reported to induce phosphory-
lation of tyrosine kinase Pyk2 in myeloid cell lines (15).
HIV-1 Env also inhibits the expression and function of a
number of chemoattractant receptors, including those for
chemokines and the bacterial chemotactic formyl peptide
fMLP on monocytes, through a CD4- and protein kinase
C–mediated receptor “desensitization” (16). More re-
cently, an X4 HIV-1 gp120 was also found to induce
CXCR4 phosphorylation and to downregulate CXCR4 in 
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human CD4
 
1
 
 T cells through activation of an src-like ty-
rosine kinase p56
 
lck
 
 (17). Consequently, the interaction of
HIV-1 Env with human cells can elicit a variety of signal-
ing events that involve both tyrosine kinase– and G pro-
tein–associated signals.
Although it is well known that HIV-1 Env induces sig-
nal transduction in host cells, such signaling events are not
thought to play a role in HIV-1 fusion/entry, but to con-
tribute to postfusion effects of HIV-1 (12–14). However,
evidence is accumulating that chemokine receptor signal-
ing triggered by direct or indirect interaction with HIV-1
Env may have a profound impact on the fusion/entry of
HIV-1. Guntermann et al. observed that preincubation of
IL-2–treated PBMCs with PTX markedly inhibited infec-
tion of the cells by X4 HIV-1, while the cells maintained a
normal level of expression of CD4 and CXCR4 on the
surface (18). The authors suggest that G
 
i
 
 protein–mediated
receptor signaling may be necessary for the competence of
CXCR4 as a viral fusion coreceptor in primary T cells. Al-
though attribution of the anti–HIV-1 effect of PTX holo-
toxin to its inhibition of G
 
i
 
 protein–mediated signaling is
inappropriate, Guntermann et al. provided the first evi-
dence that perturbation of the signaling capacity of a core-
ceptor in primary T cells could effectively block HIV-1 in-
fection. This is in contrast with a previous report in which
T lymphocyte cell line PM1 treated with PTX was still
sensitive to HIV-1 infection, albeit with a reduced produc-
tion of p24 antigen levels 10 d after infection (19). Alfano
et al. point out that the failure of PTX to block HIV-1 in-
fection of PM1 cells is presumably based on the inability of
these cells to generate signals in response to the PTX B-oli-
gomer (1). Additional evidence for a signal-dependent en-
try of HIV-1 was shown by the inhibition of viral entry in
PHA-stimulated PBMCs by cytochalasin D, a specific in-
hibitor of cytoskeletal F-actin polymerization that does not
affect cell surface expression of CD4 and HIV-1 corecep-
tors (20). Alfano et al. confirm that PTX inhibits infection
of activated PBMCs by R5 HIV-1 and indicated that the
inhibition of HIV-1 infection by PTX occurred at the
stage of viral entry (1). Furthermore, Alfano et al. demon-
strate that the anti–HIV-1 activity of PTX was in fact me-
diated by a subunit of PTX, namely the B-oligomer, which
is responsible for the binding of PTX holotoxin to the tar-
get cells and exhibits a number of biological activities on
eukaryotic cells independent of the G
 
i
 
 protein inhibitory
effect of PTX holotoxin (21). On the other hand, the entry
of X4 HIV-1 into PBMCs was affected by neither PTX
holotoxin nor B-oligomer, suggesting that the inhibitory
effect is CCR5 specific.
PTX is the major virulence factor produced by the
Gram-negative bacterium 
 
Bordetella pertussis
 
, the etiological
agent of whooping cough. PTX is a heterohexameric pro-
tein and is functionally divided into A (protomer) and B
(oligomer) domains (21). The A-protomer consists of an S1
subunit, and the B-oligomer is composed of two dimers
(S2-S4 and S3-S4) joined together by an S5 subunit (Fig. 1).
The subunits are connected by noncovalent interactions.
The A-protomer of PTX has ADP ribosyltransferase activ-
 
ity, whereas the B-oligomer confers cell surface binding
property on PTX. Due to the ADP-ribosylation activity of
the A-protomer, PTX has been a very useful pharmacolog-
ical tool for the identification of inhibitory guanine nucle-
otide binding (G
 
i
 
) proteins in the plasma membrane that are
coupled to seven-transmembrane (STM) chemokine recep-
tors, including CCR5 and CXCR4. However, A-pro-
tomer per se does not bind to the cells and therefore is in-
active in the absence of B-oligomer. In addition to the
ADP-ribosylation of G
 
i
 
-like proteins, PTX has been dem-
onstrated to elicit a number of biological events in T lym-
phocytes (22, 23), adipocytes (24), platelets (25), and mac-
rophages (26). A recent study indicated that PTX potentiates
Th1 and Th2 responses to coinjected antigen by enhancing
cytokine production and expression of costimulatory mole-
cules (27). Since these effects of PTX were displayed largely
either by biochemically purified B-oligomer or by PTX
deprived of enzymatic activity yet retaining cell binding
and signaling capacity based on phospholipase C and ty-
rosine phosphorylation pathways, it is postulated that cellu-
lar binding sites or receptor(s) for B-oligomer are critical
for the interaction of PTX with its target cells. Efforts to
characterize PTX binding sites have yielded several surface
glycoproteins in different cell types that may generate early
signaling events (21). However, whether PTX binds to dif-
ferent sites, resulting in either early cell signaling or G pro-
tein inactivation, or binds to the same site, resulting in both
these stimulatory and inhibitory effects, remains to be elu-
cidated. Another concern is whether PTX B-oligomer–
mediated cellular transmembrane signal transduction affects
the subsequent ADP-ribosylation of G
 
i
 
-like proteins. Thus,
a simple demonstration of the inhibition by PTX of a cel-
lular response to an agonist may not provide a final proof
that the agonist effect involves G
 
i
 
 protein. This argument
appears reasonable, as demonstrated by Alfano et al. (1),
who show that the inhibition of R5 HIV-1 fusion via
CCR5 by PTX can be fully accounted for by the potent
cell-activating effects of B-oligomer and the loss of the ca-
pacity of CCR5 to act as a viral fusion coreceptor.
The agonist-induced phosphorylation of STM receptors
such as CCR5 and CXCR4 can result in homologous de-
sensitization and internalization of the receptors (28, 29).
Homologous desensitization occurs in receptors in an ago-
nist-occupied state and involves phosphorylation by G pro-
tein–coupled receptor kinases. These phosphorylated re-
ceptors associate with members of the arrestin family,
resulting in a decreased affinity of the receptor for G pro-
teins and increased receptor internalization (30). Heterolo-
gous desensitization is characterized by the loss of receptor
function after phosphorylation induced by second messen-
ger–activated kinases such as protein kinase (PK)C or PKA,
as a result of activation of different receptors or signaling
processes (30). Heterologous desensitization does not in-
volve agonist occupancy of the receptor and may not lead
to arrestin-mediated receptor internalization. Since heter-
ologous desensitization has been reported to occur between
a number of STM receptors, it has been postulated to play
an important role in an orchestrated host cell response in 
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the presence of multiple stimulants. For example, activation
of two STM opiate receptors, 
 
d
 
 and 
 
m
 
, resulted in a de-
crease in phagocyte migration to a number of chemokines
(31). Furthermore, activation of 
 
d
 
 and 
 
m
 
 opiate receptors
induced chemokine receptor phosphorylation without a
change in the level of cell surface expression or agonist-
induced calcium mobilization (31). In the study by Al-
fano et al. (1), B-oligomer does not directly compete with
chemokine MIP-1
 
b
 
 for binding to CCR5-expressing PB-
MCs, suggesting that B-oligomer does not use CCR5 as its
functional receptor. However, after stimulation with B-oli-
gomer the cells showed significantly reduced calcium mo-
bilization in response to MIP-1
 
b
 
. Although the cells main-
tained a normal level of expression of CCR5 on the cell
surface after treatment with B-oligomer, C5 HIV-1 Env
gp120 could no longer induce cocapping of CD4 and
CCR5, a critical step for viral entry. These results indicate
that activation of PBMCs by B-oligomer impairs normal
signaling of CCR5 followed by a loss of its function as a fu-
sion coreceptor for HIV-1. Since B-oligomer has been re-
ported to activate PKC in human leukocytes through puta-
tive cell surface receptors, it is plausible that the attenuation
of CCR5 functioning by B-oligomer may be a conse-
quence of heterologous receptor desensitization (Fig. 1).
Despite the fact that the B-oligomer only inhibits the entry
of R5, but not X4, HIV-1 virus (1), productive infection
of X4 HIV-1 was also inhibited by long-term exposure of
cells to nontoxic concentrations of B-oligomer, as shown
by Alfano et al. Whether this is due to the disturbance of
CXCR4-related late stage cell signaling by an as yet un-
known mechanism remains to be determined.
The discovery of chemokine receptors as HIV-1 fusion
coreceptors has prompted intensified efforts to search for
novel anti–HIV-1 therapeutics by developing chemokine-
receptor antagonists. In addition to the specific chemokine
ligands for the coreceptors, modified chemokines such as
Met- or AOP-RANTES are more potent competitors of
CCR5 and more effectively inhibit HIV-1 fusion (32, 33).
Other synthetic oligopeptide and compounds have also
been reported to be highly efficacious in disrupting
CXCR4-mediated HIV-1 fusion (34, 35). An analogue of
the antibiotic Distamycin, NSC651016, by binding to and
downregulating CXCR4 and CCR5, was shown to inhibit
cell migration induced by CXCR4 or CCR5 chemokine
ligands and infection by both R5 and X4 HIV-1 (36).
These antagonists specifically interact with the fusion core-
ceptors and competitively inhibit the binding of HIV-1
Env to the cell surface. An alternative approach to inhibit-
ing HIV-1 infection is to reduce cell surface expression of
HIV-1 coreceptors. This approach is validated by the fact
that subjects with an allotypic variant of CCR5 that results
in failure to express this coreceptor on cell surface are
largely resistant to HIV-1 infection (37, 38). The anti–
HIV-1 activity of chemokines and their analogues also is in
part attributable to a rapid internalization of the fusin core-
ceptors. In addition, chemokines RANTES, MIP-1
 
a
 
, or
SDF-1
 
a
 
 that are genetically engineered to express an endo-
plasmic reticulum retrieval peptide, KDEL, at the COOH
termini can retain newly synthesized coreceptors CCR5 or
CXCR4 intracellularly, possibly by forming complexes
(39, 40). Lymphocytes transfected with these modified
chemokines (termed intrakines) were viable and resistant to
HIV-1 infection. Although many questions remain to be
resolved, the effects of the PTX B-oligomer observed by
Alfano et al. suggest an additional approach to developing
anti–HIV-1 therapeutics with the capacity to heterolo-
gously desensitize coreceptor signaling.
Figure 1. Putative effect of
PTX on cell activation. PTX
binds to a yet to be defined cell
surface receptor through the sub-
unit B-oligomer, which enables
the entry of the A-protomer.
The A-protomer inhibits Gi pro-
tein activation of CCR5 in re-
sponse to chemokines, whereas
the B-oligomer elicits a series of
cellular signaling events that may
lead to desensitization of CCR5.
DAG, diacylglycerol; GD(T)P,
guanosine di(tri)phosphate; GRK,
G protein–coupled receptor ki-
nase; IP, inositol phosphate;
MAPK, mitogen-activated pro-
tein kinase; PI3K, phosphatidyl-
inositol 3-kinase; PIP3, phos-
phatidylinositol trisphosphate;
PLC(D), phospholipase C(D). 
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